BRIEF-JCR Says Acumen Exercises Exclusive Option For Up To Two Alzheimer's Candidates

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS

0.00

June 17 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T:

  • JCR PHARMACEUTICALS CO - ACUMEN PHARMACEUTICALS EXERCISES EXCLUSIVE OPTION FOR UP TO TWO ALZHEIMER'S DISEASE CANDIDATES WITH JCR

  • JCR PHARMACEUTICALS CO - ACUMEN'S EBD PROGRAM ON TRACK FOR IND FILING IN MID-2027

  • JCR PHARMACEUTICALS CO - ELIGIBLE FOR UP TO $555 MILLION IN MILESTONE PAYMENTS FROM ACUMEN DEAL

  • JCR PHARMACEUTICALS CO - TO RECEIVE TIERED ROYALTIES ON NET SALES FROM COLLABORATION PRODUCTS

Source text: ID:nBw2fND6ra

Further company coverage: 4552.T


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.